Axsome jumps as Q1 revenue surges 57% and Alzheimer’s launch plans firm up
Axsome Therapeutics shares are higher after the company reported Q1 2026 net product revenue of $191.2 million, up 57% year over year, led by AUVELITY sales of $153.2 million (+59%). The update also highlighted AUVELITY’s April 2026 FDA approval for Alzheimer’s agitation and reiterated a June 2026 commercial launch timeline.
1. What’s moving the stock today
Axsome Therapeutics (AXSM) is trading higher after releasing first-quarter 2026 results and a business update on May 4, 2026. The company posted total net product revenue of $191.2 million, representing 57% year-over-year growth, driven primarily by AUVELITY net product sales of $153.2 million (+59% YoY), alongside SUNOSI net product revenue of $33.9 million (+34% YoY) and SYMBRAVO net product sales of $4.1 million. The report also emphasized AUVELITY’s April 2026 FDA approval for agitation associated with dementia due to Alzheimer’s disease and said the full commercial launch remains on track for June 2026.
2. Key details investors are reacting to
Beyond the headline growth, investors are focusing on the expanding commercial footprint and near-term execution milestones. Axsome said the recently announced AUVELITY salesforce expansion is substantially complete, with an expanded team of about 630 representatives, aimed at supporting continued demand in major depressive disorder and the upcoming Alzheimer’s agitation opportunity. The company also highlighted improving SYMBRAVO access, noting commercial payer coverage expanded by 17 million covered lives effective May 2026, and stated it is expanding the SYMBRAVO salesforce from 100 to 150 representatives.
3. Pipeline updates and what’s next
Axsome also flagged multiple pipeline and regulatory items that could shape expectations into mid-2026 and beyond. The company said it has submitted an NDA to the FDA for AXS-12 for cataplexy in narcolepsy and plans to announce whether the FDA accepts the filing. In addition, it reiterated planned and ongoing late-stage work for solriamfetol across several indications, including the ENGAGE Phase 3 study in binge eating disorder with topline results anticipated in the second half of 2026, and noted it acquired AXS-20 (balipodect), a PDE10A inhibitor it described as Phase 3-ready for schizophrenia and a potential option for Tourette syndrome.
4. Financial posture
Axsome reported a Q1 2026 net loss of $64.5 million and ended the quarter with $305.1 million in cash and cash equivalents as of March 31, 2026. Management maintained that existing cash is sufficient to fund anticipated operations into cash flow positivity under the current operating plan, a message that may be helping support sentiment as the company prepares for the June 2026 AUVELITY Alzheimer’s agitation launch.